Inhibition of the JAK-STAT pathway via Ruxolitinib abrogates ERKi-induced EMT and CSC enrichment in NSCLC cells, as well as impedes tumor progression in a xenograft model after ERKi treatment cessation. The gene discussed is SOAT1; the disease is non-small cell lung carcinoma.